Sinopharm Group Co Ltd
OTC:SHTDY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sinopharm Group Co Ltd
OTC:SHTDY
|
CN |
|
Nikola Corp
NASDAQ:NKLA
|
US |
|
AP Moeller - Maersk A/S
CSE:MAERSK B
|
DK |
|
C
|
CPI Card Group Inc
SWB:CPB1
|
US |
|
Sartorius AG
OTC:SSSGY
|
DE |
|
Grange Resources Ltd
ASX:GRR
|
AU |
|
S
|
State Bank of India
BSE:500112
|
IN |
|
N
|
Nomura Holdings Inc
DUS:NSE
|
JP |
|
Imperial Oil Ltd
TSX:IMO
|
CA |
|
Dwarikesh Sugar Industries Ltd
NSE:DWARKESH
|
IN |
|
8
|
88 Energy Ltd
SWB:POQ
|
AU |
|
N
|
N Citron Inc
KOSDAQ:101400
|
KR |
Wall St Price Targets
SHTDY Price Targets Summary
Sinopharm Group Co Ltd
According to Wall Street analysts, the average 1-year price target for SHTDY is 14.7 USD with a low forecast of 10.94 USD and a high forecast of 18.05 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SHTDY's stock price target?
Price Target
14.7
USD
According to Wall Street analysts, the average 1-year price target for SHTDY is 14.7 USD with a low forecast of 10.94 USD and a high forecast of 18.05 USD.
What is the Revenue forecast for Sinopharm Group Co Ltd?
Projected CAGR
5%
Over the last 14 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 5%.
What is the Operating Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
26%
Over the last 14 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 26%.
What is the Net Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
9%
Over the last 14 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 9%.
